Cita APA (7th ed.)

(17078830), Q. X., (17078833), K. H., (17078836), X. M., (17078839), Y. W., (17078842), L. Z., (17078845), L. B., . . . (17078857), Q. C. (2025). Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma.

Cita Chicago (17th ed.)

(17078830), Qingsheng Xu, et al. Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. 2025.

Cita MLA (9th ed.)

(17078830), Qingsheng Xu, et al. Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. 2025.